MedTrace Logo

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

NCT00671112 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-10-28

No results posted yet for this study

Summary

RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with bortezomib in treating patients with relapsed or refractory lymphoma.

Conditions

Interventions

DRUG

Bortezomib

Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle. The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line.

DRUG

Everolimus

Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Brian Hill, MD, PhD

    lead OTHER

Principal Investigators

  • Brian Hill, MD, PhD · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2015-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00671112 on ClinicalTrials.gov